Why the study?
Does monitoring with natriuretic peptides (N-ANP and BNP) predict anthracycline-induced reduction in left ventricular ejection fraction in patients receiving chemotherapy?
Population
107 consecutive patients receiving anthracycline as part of their chemotherapy for malignant disease
Comparison
Monitoring with natriuretic peptides vs Radionuclide left ventricular ejection fraction…
Design
Cohort
Authors
Loading...
N-ANP/BNP monitoring does not predict anthracycline-related EF decline; leaves open whether serial LVEF remains essential for cardiotoxicity surveillance.
Does monitoring with natriuretic peptides (N-ANP and BNP) predict anthracycline-induced reduction in left ventricular ejection fraction in patients receiving chemotherapy?
Natriuretic peptides (N-ANP and BNP) cannot safely substitute for serial LVEF monitoring to predict anthracycline-induced cardiotoxicity.
Daugaard et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: